NCT04673448 - Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 18, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

September 30, 2026

Conditions

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8BRCA-Associated Malignant NeoplasmBRCA Hereditary Ovarian CarcinomaMetastatic BRCA Hereditary Breast CarcinomaMetastatic Breast CarcinomaMetastatic Fallopian Tube CarcinomaMetastatic Malignant Solid NeoplasmMetastatic Ovarian CarcinomaMetastatic Pancreatic CarcinomaMetastatic Primary Peritoneal CarcinomaPrognostic Stage III Breast Cancer AJCC v8Prognostic Stage IV Breast Cancer AJCC v8Stage III Fallopian Tube Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage III Primary Peritoneal Cancer AJCC v8Stage IV Fallopian Tube Cancer AJCC v8Stage IV Ovarian Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Stage IV Primary Peritoneal Cancer AJCC v8Unresectable Breast CarcinomaUnresectable Fallopian Tube CarcinomaUnresectable Malignant Solid NeoplasmUnresectable Ovarian CarcinomaUnresectable Pancreatic CarcinomaUnresectable Primary Peritoneal Carcinoma

Interventions

BIOLOGICAL

Dostarlimab

Given IV

DRUG

Niraparib

Given PO

PROCEDURE

Biopsy

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle